Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA
DETERMINATION trial: A phase III multi-center study examining the timing of stem cell transplant for MM
The DETERMINATION study will have 1300 patients (700 in France and over 600 in the US) to determine when transplant is best used in newly diagnosed myeloma patients now that newer therapies are available. The study will also look at how the Revlimid/Velcade/Dex combo works as initial treatment and how lenalidomide affects progression as maintenance therapy.